Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling Anthony J. HatswellFleur Chandler Commentary 20 May 2017 Pages: 755 - 757
Evaluation of Healthcare Interventions and Big Data: Review of Associated Data Issues Carl V. AscheBrian SealMeredith Greer Baumgartner Leading Article 04 May 2017 Pages: 759 - 765
How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis Laura BojkeAndrea MancaStephen Palmer Practical Application 03 May 2017 Pages: 767 - 776
Defining and Measuring the Affordability of New Medicines: A Systematic Review Fernando AntoƱanzasRobert TerkolaMaarten Postma Systematic Review 05 May 2017 Pages: 777 - 791
Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics Liz MorrellSarah WordsworthRichard Barker Systematic Review Open access 29 April 2017 Pages: 793 - 804
Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal Paul TappendenChristopher CarrollMohammad Ghazavi Review Article 07 February 2017 Pages: 805 - 815
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models Chase HollmanMike PauldenChristopher McCabe Review Article 09 May 2017 Pages: 817 - 830
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States Min HuangYanyan LouVamsidhar Velcheti Original Research Article Open access 15 June 2017 Pages: 831 - 844
Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis James BuchananSarah WordsworthSamantha J. L. Knight Original Research Article Open access 31 July 2017 Pages: 845 - 858